Related Experiment Video
Updated: Apr 15, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Summary
Biosimilar medicines require rigorous evidence of efficacy and safety, differing from generics. A recent biosimilar insulin glargine demonstrated comparable efficacy and safety to the original biologic drug.
Area of Science:
- Pharmacology
- Immunology
- Regulatory Science
Background:
- Biosimilar medicines represent a distinct class of pharmaceuticals requiring extensive efficacy and safety data.
- Unlike generics, biosimilar approval necessitates comprehensive evidence beyond mere biological equivalence.
- The increasing prevalence of biologic and targeted therapies fuels the growth of the biosimilar market.
Purpose of the Study:
- To evaluate the efficacy and safety of a newly approved biosimilar insulin analogue.
- To compare the biosimilar to its originator biologic counterpart.
Main Methods:
- Regulatory review process by the European Medicines Agency (EMA).
- Analysis of registration studies assessing therapeutic efficacy and safety.
- Specific focus on immunogenicity due to the biological nature of the substances.
Main Results:
- A biosimilar insulin analogue (insulin glargine) was approved by the EMA.
- Registration studies indicated the biosimilar's efficacy and safety profile were practically identical or non-inferior to the original insulin analogue.
- Stricter registration requirements were met.
Conclusions:
- Biosimilar approval demands robust data, emphasizing efficacy and safety, including immunogenicity.
- The successful registration of biosimilar insulin glargine validates the stringent regulatory pathway.
- This indicates a promising future for biosimilar market expansion and patient access to advanced therapies.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
360
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
360
01:16Bioequivalence: Overview
2.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.3K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219
01:13Bioequivalence studies: Biowaivers
414
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
414
01:26Pharmaceutical Equivalents
267
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
267
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
333
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
333